期刊文献+

培哚普利对充血性心力衰竭患者血浆脑钠素水平的影响

下载PDF
导出
摘要 目的:探讨充血性心力衰竭(CHF)患者血浆脑钠素(BNP)水平的变化及培哚普利的干预作用。方法:78例CHF患者给予培哚普利2mg/d,1周后增加至4 mg/d,疗程4周,观测用药前后血浆BNP含量的变化。同时选择20例健康体检者为对照组。结果:CHF患者血浆BNP水平(458±218)pg/ml较对照组(21±7)pg/ml明显增高(P<0.01),CHF组BNP水平升高与心力衰竭程度呈正相关(r=0.762,P<0.01)。培哚普利治疗后血浆BNP水平明显降低,与治疗前比较差异有统计学意义(P<0.01)。不同心功能患者血浆BNP水平差异亦有区别,依次为IV级>III级>II级(P<0.01)。结论:心力衰竭时血浆BNP水平明显增高,而培哚普利具有改善心脏功能的作用。
出处 《交通医学》 2007年第6期651-652,共2页 Medical Journal of Communications
  • 相关文献

参考文献5

  • 1Mccu Hough PA,Omland T,Maisel AS.B-type riatriuretic peptides:a diagnostic breakthrough for clinicians [J].Rev Cardiovasc Med, 2003,4(2): 72-80.
  • 2王联发,吴振西,尹欣,张树林,李鲁光.心力衰竭患者血浆脑钠素含量及其与左心功能关系研究[J].疑难病杂志,2005,4(6):337-339. 被引量:16
  • 3Latini R,Masson S,de Angelis N,et al.Role of brain natriuretic peptide in the diagnosis and management of heart failure : current concepts[J].J Card Fail, 2002,8(5) : 288-299.
  • 4Ishii J,Nomura M,Nakamura Y,et al.Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure[J]. Am J Cardiol, 2002,89(6) : 691-695.
  • 5Anand IS,Fisher LD, Chiang YT,et al.Changes in brain natriuretic peptide and norepinephrine over time mid mortality and morbidity in the Valsartan Heart Failure Trial (ValHeFT)[J].Circulation, 2003,107(9) : 1278-1283.

二级参考文献10

  • 1孟春,姚荣国,郭战利.脑型钠利尿肽与心力衰竭的诊断与治疗[J].疑难病杂志,2004,3(4):250-252. 被引量:3
  • 2Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic,prognostic and therapeutic perspectives.Clin Physiol,2001,21(6):661-672.
  • 3Wieczorek ST,Wu AH,Christonson R,et al.A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure:a multicenter evaluation.Am Heart J,2002,144(5):834-839.
  • 4Tsutamoto T,Wada A,Maeda K,et al.Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.J Am Coll Cardiol,2001,37(5):1 228-1 233.
  • 5Anand IS,Fisher LD,Chiang YT,et al.Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial(Val-HeFT).Circulation,2003,107(9):1 278-1 283.
  • 6Lubien E,De Maria A,Krishnaswamy P,et al.Utility of natriureic peptide in detecting diastolic dysfunction:comparison with Doppler velocity recordings.Circulation,2002,105(5):595-601.
  • 7Wright SP,Doughty RN,Pearl A, et al.Plasma amino-terminal pro-BNP and accuracy of heart failure diagnosis in primary care:a randomized,controlled trial.J Am Coll Cardiol,2003,42(10):1 793-1 800.
  • 8Dao Q,Krishnaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.J Am Coll Cardiol, 2001,37(2):379-385.
  • 9Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the Lorsartan Intervention For Endpoint reduction in hypertention study (LIFE):a randomized trial against atenolol.Lancet,2002,359(9 311):995-1 003.
  • 10Fisher C,Berry C,Blue L, et al.N-terminal pro-BNP,but not the new putative cardiac hormone relation,predicts prognosis in patients with chronic heart failure.Heart,2003,89(8):879-881.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部